• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.

作者信息

Kirby R S, Quinn S, Mallen S, Jensen D

机构信息

Department of Urology Research, Ingleby House, St. George's Hospital, Blackshaw Road, London, UK.

出版信息

Int J Clin Pract. 2004 Jan;58(1):6-10. doi: 10.1111/j.1368-5031.2004.0031.x.

DOI:10.1111/j.1368-5031.2004.0031.x
PMID:14994963
Abstract

An analysis is presented to compare the efficacies of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) and tamsulosin in patients with benign prostatic hyperplasia (BPH), collecting data from a published 20-week, randomized, double-blind, crossover study. Results demonstrated that after 8 weeks of treatment, both doxazosin-GITS and tamsulosin provided significant (p < 0.001) improvement from baseline in total international prostate symptom score (IPSS) and obstructive and irritative subscores. Doxazosin-GITS was more effective than tamsulosin (p = 0.019 between-group difference for total IPSS; p = 0.001 for irritative subscore). Similarly, after the first 4 weeks of treatment, prior to dose titration, both doxazosin-GITS and tamsulosin provided significant (p < or = 0.001) improvement in total IPSS and subscores. Doxazosin-GITS was more effective than tamsulosin (p = 0.045 between-group difference for obstructive subscore). These data confirm that the efficacy of doxazosin is superior to that of tamsulosin in the management of patients with BPH.

摘要

相似文献

1
Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.
Int J Clin Pract. 2004 Jan;58(1):6-10. doi: 10.1111/j.1368-5031.2004.0031.x.
2
A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.坦索罗辛与控释多沙唑嗪治疗良性前列腺增生症患者的随机双盲交叉研究。
BJU Int. 2003 Jan;91(1):41-4. doi: 10.1046/j.1464-410x.2003.03077.x.
3
A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.多沙唑嗪胃肠道治疗系统、标准多沙唑嗪与安慰剂治疗良性前列腺增生症患者疗效及耐受性的双盲试验综合分析
BJU Int. 2001 Feb;87(3):192-200. doi: 10.1046/j.1464-410x.2001.02032.x.
4
Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.多沙唑嗪胃肠治疗系统与坦索罗辛治疗前列腺增生症下尿路症状的疗效比较：一项多中心、前瞻性、随机研究。
Int J Clin Pract. 2011 Nov;65(11):1193-9. doi: 10.1111/j.1742-1241.2011.02759.x.
5
A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.一项在巴西进行的随机、双盲研究，比较控释多沙唑嗪和坦索罗辛治疗良性前列腺增生的疗效和耐受性。
Int J Clin Pract. 2006 Oct;60(10):1172-7. doi: 10.1111/j.1742-1241.2006.01107.x. Epub 2006 Aug 24.
6
The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.多沙唑嗪标准制剂与胃肠道治疗系统治疗良性前列腺增生的临床疗效及耐受性
BJU Int. 2005 Mar;95(4):575-9. doi: 10.1111/j.1464-410X.2005.05342.x.
7
Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.多沙唑嗪胃肠治疗系统 4 毫克与坦索罗辛 0.2 毫克对中国下尿路症状男性夜尿的影响：一项前瞻性、多中心、随机、开放、平行研究。
Urology. 2011 Sep;78(3):636-40. doi: 10.1016/j.urology.2011.04.038. Epub 2011 Jun 21.
8
[Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].[多沙唑嗪胃肠道治疗系统（GITS）制剂与多沙唑嗪标准制剂治疗良性前列腺增生症患者的疗效及耐受性双盲试验]
Fortschr Med Orig. 2000 Jul 27;118 Suppl 2:83-92.
9
Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.多沙唑嗪胃肠治疗系统与坦索罗辛治疗良性前列腺增生症：一项针对中国患者的研究。
Int J Urol. 2007 Feb;14(2):118-22. doi: 10.1111/j.1442-2042.2007.01502.x.
10
Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.多沙唑嗪胃肠道治疗系统制剂、标准多沙唑嗪和安慰剂治疗良性前列腺增生患者的疗效及耐受性双盲试验
Eur Urol. 2000 Oct;38(4):400-9. doi: 10.1159/000020315.

引用本文的文献

1
Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study.多沙唑嗪口服疗法缓解支架相关尿路症状和疼痛：一项前瞻性、随机、对照研究。
Int Braz J Urol. 2016 Jul-Aug;42(4):727-33. doi: 10.1590/S1677-5538.IBJU.2015.0570.
2
Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.治疗良性前列腺增生相关下尿路症状的单药疗法的比较有效性和安全性：一项网状Meta分析。
Medicine (Baltimore). 2015 Jul;94(27):e974. doi: 10.1097/MD.0000000000000974.
3
A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.
一项在巴西进行的随机、双盲研究，比较控释多沙唑嗪和坦索罗辛治疗良性前列腺增生的疗效和耐受性。
Int J Clin Pract. 2006 Oct;60(10):1172-7. doi: 10.1111/j.1742-1241.2006.01107.x. Epub 2006 Aug 24.
4
Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia.
Drugs. 2005;65(14):2037-47. doi: 10.2165/00003495-200565140-00008.